← Leaderboards
Dirk M. Spitzer
Washington University
$1,509,975
Attributed
$2,799,671
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $590.1K · FY2017–24$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,799,671 · 3
By mechanism
R01$2,579,393 · 2
R41$220,278 · 1
Top collaborators
- William G Hawkins8 shared
Most similar at Washington University
Same institution · by research overlap
- William G Hawkins$8,815,633
- Delphine L Chen$4,481,188
- Andrew Eric Gelman$12,797,349
- Jonathan Edward McConathy$1,853,535
- Christina Kim Ahn Hickey$455,248
Others in their field
Other Emerging Leaders on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$243,972,016
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
Research focus
LeadDrug Delivery SystemsSmall MoleculeVariantSodium ChlorideCancer CellPancreatic AdenocarcinomaLigandsMalignant NeoplasmsTumorPharmaceutical PreparationsToxic EffectIn VitroPre-ClinicalCell DeathMalignant Neoplasm Of PancreasDoseDrug CandidateIn VivoGemcitabineApoptosisPre-Clinical ModelMediatingEvaluation
Grant awards (9)
Preclinical Development of the Novel Inhibitor of Apoptosis Proteins S2/IAPinh for Cancer Therapy$325,083
R01 · FY2024 · CA · contact PI
Preclinical development of the novel inhibitor of apoptosis proteins S2/IAPinh for cancer therapy$12,839
R01 · FY2024 · CA · contact PI
Preclinical development of the novel inhibitor of apoptosis proteins S2/IAPinh for cancer therapy$346,659
R01 · FY2023 · CA · contact PI
On the path to the clinic: Lead optimization and pathway analysis of the pancreatic cancer-selective drug conjugate SW V-49$381,250
R01 · FY2021 · CA
On the path to the clinic: Lead optimization and pathway analysis of the pancreatic cancer-selective drug conjugate SW V-49$381,250
R01 · FY2020 · CA
On the path to the clinic: Lead optimization and pathway analysis of the pancreatic cancer-selective drug conjugate SW V-49$369,812
R01 · FY2019 · CA
Advancement of ACXT-3102 for the Treatment of Pancreatic Adenocarcinoma (PDAC)$220,278
R41 · FY2019 · CA · contact PI
On the path to the clinic: Lead optimization and pathway analysis of the pancreatic cancer-selective drug conjugate SW V-49$381,250
R01 · FY2018 · CA
On the path to the clinic: Lead optimization and pathway analysis of the pancreatic cancer-selective drug conjugate SW V-49$381,250
R01 · FY2017 · CA